Outset Medical Business Summary

Outset Medical, Inc. (OM) operates a medical technology business model centered on the Tablo Hemodialysis System, utilizing a "razor-and-blade" revenue strategy. The company generates income through two primary segments: Product revenue, derived from the capital sale of Tablo consoles to hospitals and clinics, and Recurring revenue, which encompasses the sale of proprietary consumables—such as cartridges and accessories—and long-term service contracts. By integrating water purification and dialysate production into a single, compact unit, Outset simplifies the dialysis process to enable "anytime, anywhere" treatment across the continuum of care. Its primary direct competitors include Fresenius Medical Care, Baxter International, B. Braun, and Quanta Dialysis Technologies. Relative to these established incumbents, Outset positions itself as a high-growth disruptor, focusing on reducing the high infrastructure costs and clinical complexity traditionally associated with renal care in both acute and home settings. The company is led by Chair and CEO Leslie Trigg, who joined in 2014 from Warburg Pincus and has been the primary architect of the Tablo platform’s commercialization and 2020 IPO. The current leadership team includes CFO Renee Gaeta, who joined in 2025 with deep medtech financial expertise, and CTO Jean-Olivier Racine, who oversees the company’s hardware and software innovation roadmap. Other key executives include Chief Medical Officer Michael Aragon and EVP of R&D, Operations, and Service Marc Nash. Outset’s board of directors features prominent industry veterans such as Lead Independent Director D. Keith Grossman and 2026 appointee Karen Prange, formerly of Boston Scientific and Henry Schein. The company maintains a strong institutional pedigree, with notable backing from investors including Warburg Pincus, T. Rowe Price, and Mubadala Investment Company.